Zdrowie i gospodarka · 07/02/2020

FDA Announces Draft Guidance on Biosimilars and Interchangeable Biosimilars Licensure

The FDA is releasing a draft guidance that will provide recommendations for applicants seeking licensure for biosimilars or interchangeable biosimilars for fewer than all licensed conditions of use, as well as for adding new conditions of use to licensed biosimilars or interchangeable products.